首页 > 市场调查报告书 > 製药

个人化医学

市场调查报告书

商品编码

1922399

日本伴随诊断市场报告：按产品/服务、技术、适应症、最终用户和地区划分（2026-2034年）

Japan Companion Diagnostics Market Report by Product & Service, Technology (Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing, and Others), Indication, End User, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 117 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2025年，日本伴随诊断市场规模达5.16亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到13.344亿美元，2026年至2034年的复合年增长率为11.48%。癌症发生率上升、对个人化医疗的需求不断增长以及次世代定序（NGS）等技术进步是推动市场成长的主要因素。

伴随诊断是一种医学检测，旨在帮助医生确定最佳治疗方案。它透过检测患者组织或血液样本中存在的特定生物标记物，来预测患者对特定药物或治疗方法的疗效。此外，伴随诊断还能对患者复杂的生物学特征和作用机制（MOA）进行详细分析，帮助医疗专业人员了解潜在的药物副作用。伴随诊断的广泛应用在个人化医疗中体现得淋漓尽致。个人化医疗会考虑每位患者的独特特征，例如基因组成，以确定最佳治疗方案。此外，伴随诊断也被用于检测癌症患者的特定基因突变，以及识别丙型肝炎患者的生物标记。

日本伴随诊断市场的发展趋势：

日本伴随诊断市场正经历显着成长，主要驱动力是各类癌症发生率的不断攀升。这推动了对更精准、更具标靶性的癌症治疗的需求。此外，针对每位患者个别特征量身定制的个人化医疗需求日益增长，也进一步支持了市场的良好前景。同时，标靶治疗药物和疗法在各种感染疾病、心血管疾病、神经系统疾病和发炎性疾病的广泛应用，也是市场成长的关键驱动因素。日本的伴随诊断监管环境良好，促使核准的检测项目数量不断增加。此外，全球临床试验的扩展也推动了市场成长。次世代定序（NGS）和液态生物检体等诊断技术的进步至关重要，使得以往难以检测的生物标记得以识别。创新基因组技术的发展有助于识别对治疗决策至关重要的基因突变和生物标誌物，从而在推动市场成长方面发挥关键作用。此外，在预测期内，生物标记在药物开发中的应用日益广泛、对精准医疗的大量投资以及消费者对伴随诊断益处的认识不断提高等因素，预计将为区域市场提供有利的增长机会。

本报告解答的关键问题

日本伴随诊断市场目前发展状况如何？您认为未来几年它将如何发展？
新冠疫情对日本伴随诊断市场产生了哪些影响？
日本伴随诊断市场依产品/服务分類的组成是怎样的？
日本伴随诊断市场依技术分類的组成是怎样的？
日本伴随诊断市场依适应症分類的细分情况如何？
日本伴随诊断市场依最终用户分類的组成是怎样的？
请介绍日本伴随诊断市场价值链的各个环节。
日本伴随诊断的关键驱动因素和挑战是什么？
日本伴随诊断市场的结构是怎么样的？主要参与者有哪些？
日本伴随诊断市场的竞争程度如何？

Japan companion diagnostics market size reached USD 501.6 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,334.4 Million by 2034, exhibiting a growth rate (CAGR) of 11.48% during 2026-2034. The rising incidence of cancer, the growing need for personalized medicine, and continuous technological advancements like next-generation sequencing (NGS), are among the primary factors propelling the market growth.

Access the full market insights report Request Sample

Companion diagnostics refer to medical tests that aid physicians in identifying the most suitable treatment strategy. They are crafted to detect specific biomarkers present in a patient's tissue or blood sample, indicating whether the patient is likely to respond positively to a particular drug or therapeutic approach. Additionally, they delve into the intricate biological profile and mechanism of action (MOA) of patients, assisting healthcare professionals in comprehending potential medication side effects. The widespread application of companion diagnostics is evident in personalized medicine, where it takes into account the distinct characteristics of each patient, such as their genetic composition, to determine the optimal treatment course. Beyond this, there is a growing use of companion diagnostics for examining specific genetic mutations in cancer patients or identifying biomarkers in those with hepatitis C.

JAPAN COMPANION DIAGNOSTICS MARKET TRENDS:

The Japan companion diagnostics market is experiencing significant growth, primarily propelled by the increasing incidence of diverse cancer types, which is fostering the demand for more precise and targeted cancer treatments. Additionally, the escalating demand for personalized medicines, tailored to the unique characteristics of each patient, further contributes to the optimistic market outlook. Simultaneously, the widespread adoption of targeted drugs and therapies addressing various infectious, cardiovascular, neurological, and inflammatory conditions serves as another substantial growth driver. The regulatory landscape for companion diagnostics in Japan is favorable, with an increasing number of tests receiving approvals. This, coupled with the expanding number of global clinical trials, strengthens the market growth. Ongoing advancements in diagnostic technologies, such as the emergence of next-generation sequencing (NGS) and liquid biopsy, are pivotal, enabling the identification of previously challenging-to-detect biomarkers. The development of innovative genomic technologies plays a key role, facilitating the identification of genetic mutations and biomarkers crucial for guiding treatment decisions, thereby fueling market growth. Additionally, factors like the growing use of biomarkers in drug development, substantial investments in precision medicine, and heightened consumer awareness regarding the benefits of companion diagnostics are projected to present lucrative growth opportunities for the regional market over the forecasted period.

JAPAN COMPANION DIAGNOSTICS MARKET SEGMENTATION:

Product & Service Insights:

To get detailed segment analysis of this market Request Sample
Assays, Kits and Reagents
Software and Services
Assays, Kits and Reagents
Software and Services

Technology Insights:

Immunohistochemistry (IHC)
Polymerase Chain Reaction (PCR)
In-situ Hybridization (ISH)
Real-time PCR (RT-PCR)
Gene Sequencing
Others
Immunohistochemistry (IHC)
Polymerase Chain Reaction (PCR)
In-situ Hybridization (ISH)
Real-time PCR (RT-PCR)
Gene Sequencing
Others

Indication Insights:

Cancer Lung Cancer Breast Cancer Colorectal Cancer Gastric Cancer Melanoma Others
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Melanoma
Others
Neurological Diseases
Infectious Diseases
Cardiovascular Diseases
Others
Cancer Lung Cancer Breast Cancer Colorectal Cancer Gastric Cancer Melanoma Others
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Melanoma
Others
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Melanoma
Others
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Melanoma
Others
Neurological Diseases
Infectious Diseases
Cardiovascular Diseases
Others

End User Insights:

Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
Contract Research Organizations
Others
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
Contract Research Organizations
Others

Regional Insights:

To get detailed regional analysis of this market Request Sample
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the Japan companion diagnostics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan companion diagnostics market?
What is the breakup of the Japan companion diagnostics market on the basis of product & service?
What is the breakup of the Japan companion diagnostics market on the basis of technology?
What is the breakup of the Japan companion diagnostics market on the basis of indication?
What is the breakup of the Japan companion diagnostics market on the basis of end user?
What are the various stages in the value chain of the Japan companion diagnostics market?
What are the key driving factors and challenges in the Japan companion diagnostics?
What is the structure of the Japan companion diagnostics market and who are the key players?
What is the degree of competition in the Japan companion diagnostics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Companion Diagnostics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Companion Diagnostics Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Companion Diagnostics Market - Breakup by Product & Service

6.1 Assays, Kits and Reagents
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Software and Services
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)

7 Japan Companion Diagnostics Market - Breakup by Technology

7.1 Immunohistochemistry (IHC)
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Polymerase Chain Reaction (PCR)
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 In-situ Hybridization (ISH)
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Real-time PCR (RT-PCR)
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Gene Sequencing
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2020-2025)
- 7.5.3 Market Forecast (2026-2034)
7.6 Others
- 7.6.1 Historical and Current Market Trends (2020-2025)
- 7.6.2 Market Forecast (2026-2034)

8 Japan Companion Diagnostics Market - Breakup by Indication

8.1 Cancer
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Segmentation
  - 8.1.3.1 Lung Cancer
  - 8.1.3.2 Breast Cancer
  - 8.1.3.3 Colorectal Cancer
  - 8.1.3.4 Gastric Cancer
  - 8.1.3.5 Melanoma
  - 8.1.3.6 Others
- 8.1.4 Market Forecast (2026-2034)
8.2 Neurological Diseases
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)
8.3 Infectious Diseases
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Forecast (2026-2034)
8.4 Cardiovascular Diseases
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Forecast (2026-2034)
8.5 Others
- 8.5.1 Historical and Current Market Trends (2020-2025)
- 8.5.2 Market Forecast (2026-2034)

9 Japan Companion Diagnostics Market - Breakup by End User

9.1 Pharmaceutical & Biopharmaceutical Companies
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Forecast (2026-2034)
9.2 Reference Laboratories
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Forecast (2026-2034)
9.3 Contract Research Organizations
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2020-2025)
- 9.3.3 Market Forecast (2026-2034)
9.4 Others
- 9.4.1 Historical and Current Market Trends (2020-2025)
- 9.4.2 Market Forecast (2026-2034)

10 Japan Companion Diagnostics Market - Breakup by Region

10.1 Kanto Region
- 10.1.1 Overview
- 10.1.2 Historical and Current Market Trends (2020-2025)
- 10.1.3 Market Breakup by Product & Service
- 10.1.4 Market Breakup by Technology
- 10.1.5 Market Breakup by Indication
- 10.1.6 Market Breakup by End User
- 10.1.7 Key Players
- 10.1.8 Market Forecast (2026-2034)
10.2 Kansai/Kinki Region
- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2020-2025)
- 10.2.3 Market Breakup by Product & Service
- 10.2.4 Market Breakup by Technology
- 10.2.5 Market Breakup by Indication
- 10.2.6 Market Breakup by End User
- 10.2.7 Key Players
- 10.2.8 Market Forecast (2026-2034)
10.3 Central/ Chubu Region
- 10.3.1 Overview
- 10.3.2 Historical and Current Market Trends (2020-2025)
- 10.3.3 Market Breakup by Product & Service
- 10.3.4 Market Breakup by Technology
- 10.3.5 Market Breakup by Indication
- 10.3.6 Market Breakup by End User
- 10.3.7 Key Players
- 10.3.8 Market Forecast (2026-2034)
10.4 Kyushu-Okinawa Region
- 10.4.1 Overview
- 10.4.2 Historical and Current Market Trends (2020-2025)
- 10.4.3 Market Breakup by Product & Service
- 10.4.4 Market Breakup by Technology
- 10.4.5 Market Breakup by Indication
- 10.4.6 Market Breakup by End User
- 10.4.7 Key Players
- 10.4.8 Market Forecast (2026-2034)
10.5 Tohoku Region
- 10.5.1 Overview
- 10.5.2 Historical and Current Market Trends (2020-2025)
- 10.5.3 Market Breakup by Product & Service
- 10.5.4 Market Breakup by Technology
- 10.5.5 Market Breakup by Indication
- 10.5.6 Market Breakup by End User
- 10.5.7 Key Players
- 10.5.8 Market Forecast (2026-2034)
10.6 Chugoku Region
- 10.6.1 Overview
- 10.6.2 Historical and Current Market Trends (2020-2025)
- 10.6.3 Market Breakup by Product & Service
- 10.6.4 Market Breakup by Technology
- 10.6.5 Market Breakup by Indication
- 10.6.6 Market Breakup by End User
- 10.6.7 Key Players
- 10.6.8 Market Forecast (2026-2034)
10.7 Hokkaido Region
- 10.7.1 Overview
- 10.7.2 Historical and Current Market Trends (2020-2025)
- 10.7.3 Market Breakup by Product & Service
- 10.7.4 Market Breakup by Technology
- 10.7.5 Market Breakup by Indication
- 10.7.6 Market Breakup by End User
- 10.7.7 Key Players
- 10.7.8 Market Forecast (2026-2034)
10.8 Shikoku Region
- 10.8.1 Overview
- 10.8.2 Historical and Current Market Trends (2020-2025)
- 10.8.3 Market Breakup by Product & Service
- 10.8.4 Market Breakup by Technology
- 10.8.5 Market Breakup by Indication
- 10.8.6 Market Breakup by End User
- 10.8.7 Key Players
- 10.8.8 Market Forecast (2026-2034)

11 Japan Companion Diagnostics Market - Competitive Landscape

11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant

12 Profiles of Key Players

12.1 Company A
- 12.1.1 Business Overview
- 12.1.2 Product Portfolio
- 12.1.3 Business Strategies
- 12.1.4 SWOT Analysis
- 12.1.5 Major News and Events
12.2 Company B
- 12.2.1 Business Overview
- 12.2.2 Product Portfolio
- 12.2.3 Business Strategies
- 12.2.4 SWOT Analysis
- 12.2.5 Major News and Events
12.3 Company C
- 12.3.1 Business Overview
- 12.3.2 Product Portfolio
- 12.3.3 Business Strategies
- 12.3.4 SWOT Analysis
- 12.3.5 Major News and Events
12.4 Company D
- 12.4.1 Business Overview
- 12.4.2 Product Portfolio
- 12.4.3 Business Strategies
- 12.4.4 SWOT Analysis
- 12.4.5 Major News and Events
12.5 Company E
- 12.5.1 Business Overview
- 12.5.2 Product Portfolio
- 12.5.3 Business Strategies
- 12.5.4 SWOT Analysis
- 12.5.5 Major News and Events

13 Japan Companion Diagnostics Market - Industry Analysis

13.1 Drivers, Restraints, and Opportunities
- 13.1.1 Overview
- 13.1.2 Drivers
- 13.1.3 Restraints
- 13.1.4 Opportunities
13.2 Porters Five Forces Analysis
- 13.2.1 Overview
- 13.2.2 Bargaining Power of Buyers
- 13.2.3 Bargaining Power of Suppliers
- 13.2.4 Degree of Competition
- 13.2.5 Threat of New Entrants
- 13.2.6 Threat of Substitutes
13.3 Value Chain Analysis